Effect of sericin on the p38MAPK signaling pathway and NLRP3 inflammasome in the kidney of type 2 diabetic rats

DONGHUI LIU, CHENG CHEN, DANDAN WANG, ZHIHONG CHEN and CHENGJUN SONG

Departments of 1Human Anatomy and 2Physiology, Chengde Medical University, Chengde, Hebei 067000; 3Department of Anatomy, Shijiazhuang Medical College, Shijiazhuang, Hebei 050599, P.R. China

Received February 25, 2020; Accepted July 31, 2020

DOI: 10.3892/etm.2020.9397

Abstract. The present study aimed to investigate the effects of sericin on the p38MAPK signaling pathway and nucleotide-binding oligomerization domain-like receptor protein 3 (NLRP3) inflammasome in the kidney of rats with type 2 diabetes mellitus (T2DM). A total of 36 male Sprague-Dawley rats were randomly divided into the normal group, T2DM model group and sericin group (n=12 rats/group). A T2DM model was developed through intraperitoneal injection of streptozotocin (35 mg·kg⁻¹·d⁻¹ for 2 consecutive days), and a high-fat and high-sugar diet. The T2DM rats in the sericin group were administered 2.4 g·kg⁻¹·d⁻¹ sericin for 35 days, and rats in the other groups were administered an equal volume of normal saline for 35 days. Fasting blood glucose was measured using the glucose oxidase method. Kidney tissue morphology was observed by H&E staining. Immunohistochemistry, western blotting, ELISA and reverse transcription-quantitative PCR were used to detect the levels of MKK6, p38MAPK, phosphorylated (p)-p38MAPK, NF-κB, IL-1β, IL-6, NLRP3 and caspase-1 in rat kidney tissues. The results revealed that blood glucose concentration, and the expression levels of MKK6, p-p38MAPK, NF-κB, IL-1β, IL-6, NLRP3 and caspase-1 were significantly reduced in the sericin group compared with those in the normal group (P<0.05). In addition, obvious pathological changes were observed in the T2DM group. Conversely, glucose concentration, and the expression levels of MKK6, p-p38MAPK, NF-κB, IL-1β, IL-6, NLRP3 and caspase-1 were significantly reduced in the sericin group compared with those in the T2DM group (P<0.05). The pathological changes were also obviously reduced. Notably, there was no significant difference in p38MAPK expression among the three groups (P>0.05). Collectively, the present study revealed that sericin may downregulate the expression levels of MKK6, p-p38MAPK, NF-κB, IL-1β, IL-6, NLRP3 and caspase-1, and inhibit activation of renal p38MAPK signaling and NLRP3-associated inflammation, which in turn may protect against kidney damage caused by T2DM.

Introduction

Diabetic nephropathy (DN) is one of the most common and serious chronic complications of diabetes. Without appropriate treatment, DN can progress to end-stage renal disease (1,2); however, the pathogenesis of DN is complex and unclear. Previous studies have revealed that DN is associated with genetic susceptibility, abnormal renal hemodynamics, oxidative stress and inflammatory response (3-5). The p38MAPK signaling pathway is an important branch of the MAPK pathway, which is activated in the kidney, and can promote glomerulosclerosis and tubulointerstitial fibrosis by participating in inflammatory reactions and oxidative stress (6). Nucleotide-binding oligomerization domain-like receptor protein 3 (NLRP3) inflammasome is a molecular platform that activates caspase-1. The NLRP3 inflammasome can regulate the maturation and secretion of pro-inflammatory cytokines, and can thus regulate the chronic inflammatory response (7,8). Sustained hyperglycemia in type 2 diabetes mellitus (T2DM) can activate the p38MAPK signaling pathway and the NLRP3 inflammasome, which can affect the occurrence and development of DN by regulating the expression of downstream related factors (9-11). Therefore, studying changes in the p38MAPK signaling pathway and NLRP3 inflammasome in the kidneys of patients with diabetes may be of great significance for further study of the pathogenesis of DN.

At present, the clinical treatment of T2DM includes improving diet, appropriate exercise, drug control of blood glucose and surgery (12-14). Most of these drugs can control blood glucose well, but long-term use is prone to drug resistance and adverse reactions (3,14). For example, oral hypoglycemic drugs such as sulfonylureas, biguanides and insulin sensitizers can cause drowsiness and gastrointestinal reactions (13). After subcutaneous injection, allergic reactions, sarcoidosis and blood stasis may occur. In addition, it may
cause lipolysis under the skin, which will lead to unstable insulin absorption, and it is very difficult to resolve spontaneously once it occurs (14). Therefore, it is necessary to identify a drug with reliable therapeutic effect, fewer adverse reactions and good kidney protection.

Sericin is a water extract obtained from the cocoon of silkworms (Bombyx mori) and is a natural water-soluble protein. It has been demonstrated that sericin can effectively reduce blood glucose in rats with T2DM and protect against diabetes-induced kidney damage (15,16). However, the underlying mechanism is currently unclear. The present study aimed to investigate the protective effects and underlying mechanism of sericin on kidney injury in rats with T2DM. Changes in key proteins associated with the p38MAPK signaling pathway and NLRP3 inflammasome were analyzed. The present findings may provide novel insights for the prevention and treatment of T2DM and its complications.

Materials and methods

Animals. Male Sprague-Dawley rats (n=42; weight, 170-190 g; age, 5-6 weeks) were purchased from Beijing Vital River Laboratory Animal Technology Co., Ltd. and were maintained under standard conditions (Temperature, 20-24°C; humidity, 50-55%; free access to food and water; 12/12 h light/dark cycle). The health and behaviors of the rats were monitored every day. The main humane endpoints of reduced heart rate and respiration rate were used to determine when animals should be euthanized. All animal experimental procedures were approved by the Ethics Committee of Chengde Medical University (Chengde, China).

Establishment of a rat model of T2DM. A rat model of T2DM was established in 30 rats according to previous studies (17-19). Briefly, rats were fed a high-fat and high-sugar diet (59% of basic feed, 20% of white sugar, 3% of egg yolk, 18% of lard) for 4 weeks (20,21), and were then intraperitoneally injected with 35 mg·kg⁻¹·d⁻¹ streptozotocin (Sigma-Aldrich; Merck KGaA) for 2 days. If fasting blood glucose was ≥11.1 mmol·l⁻¹ for three consecutive measurements at 72 h after the last injection, the T2DM model was considered successfully established. During model establishment, six rats died (22-24).

Animal grouping and treatment. After successful T2DM modeling, the rats continued to be fed with a high-fat and high-sugar diet for 4 weeks (17). Subsequently, the T2DM model rats were randomly divided into the T2DM model group and the sericin group (n=12 rats/group). Rats in the sericin and T2DM model groups were administered 2.4 g·kg⁻¹·d⁻¹ sericin by gavage and an equal volume of normal saline, respectively, for 35 days. In parallel, rats in the normal group (fed with a normal diet ad libitum; n=12) were administered an equal volume of normal saline for 35 days. After treatment for 35 days, the rats in each group were fasted for 12 h. Blood samples were collected via the tail vein for blood glucose testing once a week; 5-10 µl blood was collected each time. Kidney tissues were collected following anesthesia (intraperitoneal injection of 300 mg/kg 10% chloral hydrate) and sacrifice by decapitation. During anesthesia, the rats did not exhibit any signs of peritonitis, pain or discomfort.

Detection of blood glucose levels. Blood samples from each group of rats were centrifuged at 800 x g for 20 min at 4°C. The serum was then collected and glucose levels were detected using the Beckman Coulter AU5800 Automatic Biochemical Analyzer (Beckman Coulter, Inc.).

H&E staining. The kidney morphology of each group was observed by H&E staining. Briefly, kidney samples were fixed in Bouins fixative liquid [a mixture of picric acid saturated liquid (1.22%), formaldehyde and glacial acetic acid in a ratio of 15:5:1] at room temperature for 24 h, embedded in paraffin and cut into 5-µm sections. The sections were stained with hematoxylin (room temperature for 7 min), eosin (room temperature for 1 min), dehydrated in gradient ethanol and incubated with xylene (room temperature for 30 min). The samples were then observed under a light microscope (OLYMPUS BH-2; Olympus Corporation).

Immunohistochemistry. Kidney tissue sections were incubated with 3% H₂O₂-methanol for 30 min at 37°C to inactivate endogenous peroxidase activity. Antigen retrieval was then performed in a microwave for 8 min with 0.01 M citrate buffer (pH, 6.0). Subsequently, tissue sections were incubated with the following primary antibodies at 4°C overnight: MKK6 (1:100; cat. no. A2575; Wuhan Aibotek Biotechnology Co., Ltd.), phosphorylated (p)-p38MAPK (1:50; cat. no. sc-166182;Santa Cruz Biotechnology, Inc.), NF-κB (1:50; cat. no. ab16502; Abcam), NLRP3 (1:100; cat. no. DF7438; Affinity Biosciences), caspase-1 (1:200; cat. no. A0964; Wuhan Aibotek Biotechnology Co., Ltd.), IL-1β (1:200; cat. no. AF5103; Affinity Biosciences) and IL-6 (1:200; cat. no. DF6087; Affinity Biosciences). After washing with PBS, secondary antibodies (1:300; Biotin labeled goat anti-rabbit IgG polymer; cat. no. SP-9001;Beijing Zhong Shan-Golden Bridge Biological Technology Co., Ltd.) were added and incubated at 37°C for 40 min. After DAB staining at room temperature for 2 min, hematoxylin counterstaining was performed at room temperature for 3 min. Brownish yellow and/or tan particles in the glomeruli and/or renal tubules were considered positive staining. Six rats were randomly selected from each group, and three non-continuous kidney slices were randomly selected from each rat. Three non-overlapping fields containing glomeruli and tubules were randomly selected for observation in each slice. The integrated optical density value of the positive staining in each visual field was calculated using Image-ProPlus 6.0 software (Media Cybernetics, Inc.), and the average optical density value was taken as the relative expression level of the target protein.

Western blotting. Total protein was extracted from kidney tissues using the RIPA (cat. no. R0020, Beijing Soleibao Technology Co., Ltd.) and quantified using the BCA protein concentration determination kit (cat. no. PC0020, Beijing Soleibao Technology Co., Ltd.). Total protein (60 µg) was separated by SDS-PAGE on 10-12% gels and was then transferred onto PVDF membranes (cat. no. IEVH10100; EMD Millipore). After blocking with 5% non-fat milk at room temperature for 1 h, membranes were incubated with the following primary antibodies at room temperature for 2 h: MKK6 (1:500; cat. no. A2575; Wuhan Aibotek Biotechnology Co., Ltd.), p-p38MAPK

LIU et al.: EFFECTS OF SERICIN ON p38MAPK SIGNALING AND NLRP3 INFLAMMASOME IN T2DM
EXPERIMENTAL AND THERAPEUTIC MEDICINE 20: 267, 2020

Table I. Primers used in this study.

| Gene    | Sequence (5'-3') | Primer length (bp) |
|---------|-----------------|--------------------|
| MKK6    | F: AACGGCCCCACGTATCCAGAG 147 |
|         | R: CCACCAATCCACAGTGGGCTCA |
| p38MAPK | F: TTACCGATGACCCAGTTCAGGTTTC 107 |
|         | R: AGCGAGGTGTCGGGCTT |
| NF-κB   | F: GATGGGACACCATCCTACACATA 130 |
|         | R: CCCAAGAGTGTCAGGGT |
| IL-1β   | F: CCCTGAACACTAAGTGAATAAGCA 111 |
|         | R: CCAAGTGCAAGGCTGGAAG |
| IL-6    | F: ATTGTATGAAACAGCGGATGACAC 150 |
|         | R: CCAGCTAGAAACGGAATCCTGGA |
| NLRP3   | F: CTGAACATGCTCCTGGAAC 87 |
|         | R: AACCAATGCGAGATCTCGACAC |
| Caspase-1| F: ACTCGTACACGTCTTGCCCTCA 190 |
|         | R: CTGGGCCAGGCCAGAAATT |
| GAPDH   | F: GCCACAGTCGCAAGGCTGAAATG 143 |
|         | R: ATGGTGCTGGAAGAAGCGGCA |

F, forward; R, reverse; NLRP3, nucleotide-binding oligomerization domain-like receptor protein 3.

(1:500; cat. no. AF6456; Affinity Biosciences), p-p38MAPK (1:1,000; cat. no. sc-166182; Santa Cruz Biotechnology, Inc.), NF-κB (1:2,000; cat. no. ab16502; Abcam), NLRP3 (1:1,000; cat. no. DF7438; Affinity Biosciences), caspase-1 (1:500; cat. no. A0964; Wuhan Aibotek Biotechnology Co., Ltd.) and β-actin (1:500; cat. no. AF7018; Affinity Biosciences). The secondary antibody (1:10,000; cat. no. 074-1806; KPL, Inc.) was then added and the membranes were incubated at room temperature for 1.5 h. Subsequently, the membranes were washed and subjected to color development using the Super ECL Plus ultra-sensitive luminescent solution (cat. no. P1050; Beijing Pulilai Gene Technology Company). The gray intensities of each band were measured using Quantity One-v 4.6.2 software (Bio-Rad Laboratories, Inc.). The ratio of the gray value of the target protein to β-actin was taken as the relative expression level of each target protein.

ELISA. The detection of IL-1β and IL-6 in serum was performed using the Rat IL-1β/IL-6 ELISA kit (RayBiotech, Inc.; IL-1β, cat. no. Q63264; IL-6 cat. no. P20607), according to the manufacturer's protocol. The absorbance was measured at 450 nm using a microplate reader (ELX808; BioTek Corporation). The corresponding concentration was then calculated.

Reverse transcription-quantitative PCR (RT-qPCR). Total RNA was extracted from 100 mg kidney tissue using the TaKaRa MiniBEST Universal RNA Extraction kit (cat. no. 9767; Takara Biotechnology Co., Ltd.). cDNA was then generated by using the PrimeScript™ RT Master Mix (Takara Biotechnology Co., Ltd.; cat. no. RR036A) at 37°C for 15 min, and 85°C for 5 sec. The mRNA expression levels of MKK6, p38MAPK, NF-κB, IL-1β, IL-6, NLRP3, caspase-1 and GAPDH genes were detected with RT-qPCR. The primer sequences are listed in Table I. qPCR was performed using 12.5 µl SYBR Premix Ex TaqII (Takara Biotechnology Co., Ltd.; cat. no. RR820A), 1 µl PCR forward primer, 1 µl PCR reverse primer, 2 µl cDNA and 8.5 µl ddH2O. The thermocycling conditions were as follows: 95°C for 30 sec, followed by 40 cycles at 95°C for 5 sec and 60°C for 30 sec, and a final step at 60°C for 5 min. The relative expression level of each target gene was analyzed using the 2^−ΔΔCq method (25).

Statistical analysis. Data were analyzed using IBM SPSS Statistics 21.0 statistical software (IBM Corp.). Data are presented as the mean ± SD of three independent experiments. Multi-group comparisons were performed by one-way ANOVA and pairwise comparisons were conducted using LSD-t post hoc test. P<0.05 was considered to indicate a statistically significant difference.

Results

Sericin reduces blood glucose levels in rats. To investigate the effects of sericin on blood glucose levels, blood glucose was measured using the glucose oxidase method. The blood glucose of rats in the normal, T2DM model and sericin groups was 10.83±2.03, 29.45±4.82 and 13.20±4.09 mmol·L⁻¹, respectively (Table II). The blood glucose levels in the T2DM model group were significantly higher than those in the normal group (P<0.05), whereas those in the sericin group were significantly lower than those in the T2DM model group (P<0.05).

Sericin relieves the T2DM-induced pathological changes to the rat kidney. To further address the effects of sericin, H&E staining was conducted to detect the morphological structure of rat kidneys in each group. Compared with in rats in the normal group, renal glomerular hypertrophy and mesangial hyperplasia,
thickened basement membrane and extracellular matrix accumulation were detected in the T2DM model group (Fig. 1). The renal pathological manifestations in the sericin group were obviously reduced. The renal mesangial hyperplasia, basement membrane thickening and renal interstitial fibrosis were milder in the sericin group than those in the T2DM model group.

Sericin suppresses the expression of p38MAPK signaling pathway-related proteins and genes in the rat kidney. The present study measured the effects of sericin on the expression levels of p38MAPK signaling pathway-related proteins. The positive staining of MKK6, p-p38MAPK, NF-κB, IL-1β and IL-6 protein was shown as brownish yellow and/or brown granules, which were mainly distributed in renal tubular epithelial cells and mesangial cells (Fig. 2A). The protein expression levels of MKK6, p-p38MAPK, NF-κB, IL-1β and IL-6 were highest in the T2DM model group and lowest in the normal group (Fig. 2B). The results of western blotting are shown in Fig. 3A. Clear MKK6, p38MAPK, p-p38MAPK, NF-κB and β-actin bands were observed at 37, 43, 43, 45 and 42 kDa, respectively. The protein expression levels of MKK6, p-p38MAPK and NF-κB were highest in the T2DM model group and lowest in the normal group (Fig. 3B). Levels of IL-1β and IL-6 were further analyzed using ELISA (Fig. 3C). The results showed that the protein and mRNA expression levels of MKK6, p-p38MAPK and NF-κB in the kidneys of the T2DM model group were significantly higher than those in the normal group (P<0.05); while those in the sericin group were significantly lower than those in the T2DM model group (P<0.05). The protein expression levels of p-p38MAPK were significantly higher in the kidney of rats in the T2DM model group than those in the normal group (P<0.05), whereas the protein expression levels of p-p38MAPK were significantly lower in the kidney of rats in the sericin group compared with those in the T2DM model group (P<0.05). However, there was no significant difference in the mRNA and protein expression levels of p38MAPK in each group of rats (P>0.05). Taken together, these results indicated that sericin reduced the expression of p38MAPK signaling pathway-related genes and proteins in rat kidney samples.

Figure 1. Morphological structure of the rat kidney in each group. H&E staining was performed to observe the pathological changes in the normal, T2DM model and sericin groups. Black arrows: Mesangial matrix; Green arrows: Mesangial cells; Red arrows: Basement membrane. Scale bar, 50 µm. T2DM, type 2 diabetes mellitus.

Sericin reduces the expression of NLRP3 and caspase-1 in the kidneys of rats. The present study further tested the effects of sericin on the expression levels of NLRP3 and caspase-1. Using immunohistochemistry, NLRP3 and caspase-1 proteins were shown as brownish yellow and/or tan granules. NLRP3 protein was mainly expressed in the cytoplasm of renal tubular epithelial cells, and caspase-1 protein was mainly expressed in renal tubular epithelial cells and mesangial cells (Fig. 4A). The protein expression levels of NLRP3 and caspase-1 were highest in the T2DM model group and lowest in the normal group (Fig. 4B). The results of western blotting are shown in Fig. 5A. Clear NLRP3, caspase-1 and β-actin bands were seen at 118, 45 and 42 kDa, respectively. Consistently, the protein expression levels of NLRP3 and caspase-1 were highest in the T2DM model group and lowest in the normal group (Fig. 5B). RT-qPCR was conducted to detect their expression at the mRNA level (Fig. 5C). The results showed that the protein and mRNA expression levels of NLRP3 and caspase-1 were significantly higher in the kidney of rats in the T2DM model group than those in the normal group (P<0.05). Conversely, their expression levels were significantly lower in the kidney of rats in the sericin group compared with those in the T2DM model group (P<0.05). These results indicated that sericin may reduce the expression of NLRP3 and caspase-1 in the kidneys of rats.

Table II. Blood glucose levels of each group.

|                     | Normal group | T2DM model group | Sericin groups |
|---------------------|--------------|------------------|---------------|
| Blood glucose (mmol·l⁻¹) | 10.83±2.03  | 29.45±4.82ᵃ      | 13.20±4.09ᵇ   |

ᵃP<0.05, compared with normal group;ᵇP<0.05, compared with T2DM model group.
Discussion

T2DM is a chronic metabolic disease characterized by insulin resistance and multiple organ damage, which often occurs in the kidneys and can cause DN. DN is one of the serious microvascular complications of T2DM (26,27). Typical pathological changes of DN include hypertrophy of renal cells, thickening of the glomerular basement membrane and accumulation of the extracellular matrix, which can further cause glomerulosclerosis and tubulointerstitial fibrosis, and eventually lead to renal insufficiency or renal failure (28,29). The pathogenesis of DN has not yet been fully elucidated, but scholars have recognized that it is caused by the participation of multiple risk factors in a certain genetic background, and the inflammatory response is known to have an important role (30,31).

The p38MAPK signaling pathway can regulate the inflammatory response of the kidney and is one of target pathways of anti-inflammatory drugs (32). The p38MAPK signaling pathway is characterized by a three-level kinase cascade; under the action of hyperglycemia, MAPK kinase is phosphorylated first, and then the threonine-tyrosine site in the p38MAPK domain is phosphorylated to activate p38MAPK by activating MKK6, which becomes p-p38MAPK (6,33). The biological activity of p-p38MAPK further induces NF-κB, which is a crucial transcription factor in the inflammatory response.
allowing it to enter the nucleus from the cytoplasm, where it binds to the target gene promoter or enhancer to activate IL-1β and IL-6, thus inducing inflammation (34,35). IL-1β and IL-6 are important regulators of inflammation. IL-1β can stimulate the proliferation of mesangial cells and release reactive oxygen to participate in kidney inflammation (36,37). IL-6 is involved in the inflammatory response of the kidney through promoting mesangial cell proliferation, extracellular matrix synthesis and local infiltration of macrophages in renal tissues, and can accelerate glomerular sclerosis, lead to tubular atrophy and interstitial fibrosis, and thereby advance the progression of DN (37,38). The present study revealed that fasting blood glucose, and the expression levels of renal MKK6, p-p38MAPK, NF-κB, IL-1β and IL-6 were significantly higher in the T2DM model group compared with those in the normal group. These findings indicated that under hyperglycemia, the p38MAPK signaling pathway was activated in the rat kidney, which may induce the activation of downstream inflammatory cells and promote the expression of inflammatory mediators. This may therefore lead to an increase in the production of inflammatory factors that affect the kidney tissue, and cause changes in kidney morphology and function. In addition, hyperglycemia may stimulate the renal p38MAPK signaling pathway to further induce oxidative stress and accelerate the process of renal fibrosis, whereas oxidative stress can also activate the p38MAPK signaling pathway. This vicious cycle may further promote the occurrence and development of DN (34,39). Notably, p38MAPK is biologically active only in the form of p-p38MAPK; therefore, no significant difference was detected in p38MAPK expression between the groups of rats in the present study.

The NLRP3 inflammasome is an important part of the immune inflammatory response and has been reported to serve an important role in the occurrence and development...
of DN (40). The NLRP3 inflammasome consists of NLRP3, caspase-1 and apoptosis-related speckle-like protein. Under the stimulation of hyperglycemia, the domain of NLRP3 is changed and the caspase-1 precursor is cleaved to generate active caspase-1 with hydrolase activity. Activated caspase-1 can promote the processing of inactive IL-1β precursors, and also induce the maturation and secretion of IL-1β to participate in the inflammation of the kidney (41-43). Notably, elevated IL-1β levels can also activate NF-κB in renal tubular epithelial cells, further amplifying the inflammatory response and accelerating the process of renal fibrosis (44). In the present study, the expression levels of NLRP3 and caspase-1 were significantly higher in the kidney of rats in the T2DM model group compared with those in the normal group, thus suggesting that under hyperglycemic conditions, the NLRP3 inflammasome may be activated, which could further aggravate the inflammatory response of the kidney, causing significant pathological changes in the kidneys of the T2DM model group rats.

DN is a fatal chronic complication of diabetes. Once it develops into end-stage renal disease, severe and complex metabolic disorders often occur, resulting in poor prognosis (45). Therefore, only with early targeted prevention and treatment of DN can further development of kidney damage be effectively controlled and delayed. At present, the treatment of clinical DN is mainly based on hypoglycemic, antihypertensive, lipid-lowering and anti-inflammatory therapies, and other measures (46). Although various hypoglycemic drugs can control blood glucose, long-term administration is prone to induce drug resistance, and liver and kidney damage. Therefore, a large number of studies have focused on natural drugs that have a reliable hypoglycemic effect and exhibit kidney protection (47-49). Sericin is a natural water-soluble protein found in silk cocoons, which is composed of 18 amino acids. In the molecular structure, hydroxyl, carboxyl and amino groups of amino acids with strong polar side groups account for the vast majority (50). Sericin is biodegradable and has no toxic side effects on the human body. In China, silkworm cocoons soaked in boiling water have been reported to reduce blood glucose (51). Our previous studies also demonstrated that sericin was able to lower blood glucose and protect organs, such as the liver, kidney and islet cells (16,52,53); however, the specific underlying mechanism is still unclear. In the present study, the rats were treated with sericin by gavage. The levels of fasting blood glucose, and the expression levels of MKK6, p-p38MAPK, NF-κB, IL-1β, IL-6, NLRP3 and caspase-1 in the kidney were lower in the sericin group than those in the T2DM model group. In addition, the pathological changes in the kidneys of the sericin group were markedly reduced. These findings indicated that the expression of related factors in the p38MAPK signaling pathway and NLRP3 inflammasome in the kidney of rats with T2DM changed following gavage treatment with sericin. Therefore, sericin may reduce blood glucose and renal injury in T2DM rats by regulating these factors.

The present study had some limitations. Firstly, there was a lack of experiments on the interaction between sericin and the p38MAPK signaling pathway in models without hyperglycemia. Secondly, the phosphorylation levels of related factors in the p38MAPK signaling pathway were not analyzed due to the limited amount of kidney tissues and the unavailability of the antibody. Further studies are thus warranted.

In conclusion, the present study demonstrated that sericin reduced blood glucose, and inhibited activation of the p38MAPK signaling pathway and NLRP3 inflammasome in the kidney of rats with T2DM. These effects may reduce inflammation, weaken T2DM-induced kidney damage, and delay the occurrence and development of DN.

Acknowledgements

Not applicable.

Funding

The current study was supported by the National Natural Science Foundation of China (grant no. 81441133) and the Natural Science Foundation of Hebei Province (grant no. H2013406096).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

DL wrote the manuscript, performed the experiments and analyzed the data. CC and DW collected the data. ZC and CS conceived the idea, designed the study, provided technical support and revised the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

All animal experimental procedures were approved by the Ethics Committee of Chengde Medical University.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. He Y, Zhang L, Fang Z, Jiang H, Liu X and Sun J: Regulation of Qizhen Jiangtang Granules on TGF-β1/Smad signaling pathway in rats with diabetic nephropathy. J Anhui Univ Tradit Chin Med 39: 50-55, 2020.
2. Zhang J: The effect of calcium dobesilate capsule combined with ramipril in the treatment of early diabetic nephropathy. Henan Medical Res 28: 2020-2021, 2019.
3. Chen X and Fang M: Oxidative stress mediated mitochondrial damage plays roles in pathogenesis of diabetic nephropathy rat. Eur Rev Med Pharmacol Sci 22: 5248-5254, 2018.
4. Manna K, Mishra S, Saha M, Mahapatra S, Saha C, Yenge G, Nilesh Gaikwad, Pal R, Oulkar D, Banerjee K and Das Saha K: Amelioration of diabetic nephropathy using pomegranate peel extract-stabilized gold nanoparticles: Assessment of NF-κB and Nrf2 signaling system. Int J Nanomedicine 7: 1753-1777, 2019.
5. Sharma D, Bhattacharya P, Kalia K and Tiwari V: Diabetic nephropathy: New insights into established therapeutic paradigms and novel molecular targets. Diabetes Res Clin Pract 128: 91-108, 2017.
6. Cheng YX, Yang LL and Lin Y: Research progress on the relationship between p38MAPK signaling pathway and glomerular disease. Shandong Medical J 58: 98-101, 2018.

7. Wang S, Jiang MF and Kang KD: p38 MAPK and NF-kB: Inflammation and autoimmune diseases. Trends Mol Med 17: 56-74, 2011.

8. Xuan HY, Chen YY and Wang CL: Inflammatory mediators and kidney diseases. J Nephrol Dial Ren Transpl 27: 369-373, 2018.

9. Guo Y, Song Z, Zhou M, Yang Y, Zhao Y, Liu B and Zhang X: Infiltrating macrophages in diabetic nephropathy promote podocytes apoptosis via TNF-α-ROS-p38 MAPK pathway. Oncotarget 8: 55276-53287, 2017.

10. Wang X, Shi L, Han Z and Liu B: Follistatin-like 3 suppresses cell proliferation and fibronectin expression via p38 MAPK pathway in rat mesangial cells cultured under high glucose. Int J Mol Sci 15: 4114-4121, 2014.

11. Luo B, Li B, Wang W, Liu X, Liu X, Xia Y, Zhang C, Zhang Y, Zhang M and An F: Rosuvastatin alleviates diabetic cardiomyopathy by inhibiting NLRP3 inflammasome and MAPK pathways in a type 2 diabetes rat model. Cardiovasc Drugs Ther 28: 33-43, 2014.

12. Xueyun X and Hanli C: The clinical effect of Yin Huo Xuongtai Decoction in adjunctive treatment of type 2 diabetic peripheral neuropathy. Inner Mongolia Tradit Chin Med 39: 9-41, 2020.

13. Lu M: Evaluation of the efficacy and drug side effects of Baitangping and metformin in the treatment of type 2 diabetes. World Latest Medical Information Abstracts 18: 100-101, 2018.

14. Wang Q and Xin M: Subcutaneous injection of insulin causes local skin adverse reactions. Chin J Dermatol 48: 65-67, 2015.

15. Fu XM, Zhong MR and Fu WL: Effect of serum homocysteine, blood lipids and microvascular complications on type 2 diabetes. Chin J Lab Diagn 24: 1114-1117, 2020.

16. Yang W, Lu J, Weng J, Jia W, Ji L, Xiao J, Shan Z, Liu J, Tian H, Ji Q, et al.: Prevalence of diabetes among men and women in China. N Engl J Med 362: 1090-1010, 2010.

17. Guo L, Meng H and Gao A: Changes and significance of inflammatory factors and oxidative stress indicators in patients with diabetic nephropathy in different stages. J Inner Mongolia Med Univ 41: 370-373, 2019.